Detalles de la búsqueda
1.
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Oncologist
; 22(11): 1301-1308, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28701571
2.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Breast Cancer Res Treat
; 156(1): 81-9, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26909792
3.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
N Engl J Med
; 363(23): 2200-10, 2010 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-21121833
4.
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Breast Cancer Res Treat
; 132(3): 819-31, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21960110
5.
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
J Clin Oncol
; 38(3): 203-213, 2020 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31804894
Resultados
1 -
5
de 5
1
Próxima >
>>